Biopharmaceutical major Biocon said on Monday that Biocon Pharma, a wholly owned subsidiary, has unveiled generic drugs in Brazil, the world’s sixth-largest population, in conjunction with Brazilian firm Libbs Pharmacutica.
As part of the out-licensing deal, the Biocon arm will be responsible for drug development and manufacturing, while Libs will leverage its expertise and access to imports, distribution, and markets in Brazil, subject to approval from health regulator ANVISA.
The partnership, which marks the entry of Biocon’s general formulations into Latin America, sought to build a successful collaboration with Libs starting in 2017 to introduce the biosimilar trastuzumab in Brazil.
Biocon CEO and MD Siddharth Mittal said that “expanding our collaboration with Libbs Pharmacutica to our general formulations will help us get started with Brazil in Latin America.”
Commercial head-global generics Abhijeet Zutshi said that this partnership advances Biocon’s ability to integrate its portfolio of complex and differentiated APIs.
.
Add Comment